# A Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors

> **NCT07328217** · PHASE1,PHASE2 · RECRUITING · sponsor: **Dizal Pharmaceuticals** · enrollment: 203 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** GW5282
- **DRUG:** GW5282

## Key facts

- **NCT ID:** NCT07328217
- **Lead sponsor:** Dizal Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-29
- **Primary completion:** 2028-12
- **Final completion:** 2029-06
- **Target enrollment:** 203 (ESTIMATED)
- **Last updated:** 2026-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07328217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07328217, "A Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07328217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*